Dear Colleagues,

Here is the EFPIA Daily Briefing for 16 November 2016. Any feedback would be most welcome.

Best wishes,

Faraz Kermani, Communications Manager (External Affairs)

Generics

- **Generic heart failure drug costs too high for many uninsured-study** - (Yahoo!News via NewsPoints Desk)
  (15/11/2016) (FirstWord Pharma)
  Research data published at the American Heart Association medical meeting reveal wide discrepancies in the cost of generic treatments for heart failure for uninsured patients, even among pharmacies in the same area.

Clinical Trials

- **Two Studies Reveal Differences In Real-World Treatment Patterns In Rheumatoid Arthritis Patients Taking REMICADE (infliximab) Compared To CT-P13 (infliximab biosimilar)**
  (14/11/2016) (FirstWord Pharma)
  Studies presented at the 2016 ACR/ARHP Annual Meeting reveal higher discontinuation rates in patients newly beginning or switching to treatment with CT-P13.

AMR

- **Stop demanding antibiotics for children with conjunctivitis, royal college tells schools**
  (14/11/2016) (British Medical Journal)
  An estimated 160,000 appointments annually could be freed up at UK general practices if schools stopped sending home children with infective conjunctivitis, the RCGP says.

Companies

- **Roche Launches Immunotherapy Research Network**
  (15/11/2016) (PharmTech.com)
  Roche has launched immunotherapy Centers of Research Excellence (imCORE), a global network of cancer researchers focused on developing new treatments.
Specific Disease Areas

- **Respiratory illnesses and their cost to European governments**
  (16/11/2016) (EurActiv.com)
  4mn Europeans live in homes that are too damp, with 2.2mn suffering asthma as a direct consequence. European governments’ expenditure on asthma and COPD amounts to €82bn annually.

- **Stress urinary incontinence drug’s benefits do not outweigh harms**
  (15/11/2016) (Medical News Today)
  A new study indicates that the benefits of duloxetine, a drug used in Europe to treat stress incontinence in women, do not outweigh the harms.

- **High-intensity statin treatment increases chance of survival**
  (15/11/2016) (The Pharmaceutical Journal)
  Analysis of data from more than 500,000 patients with atherosclerotic cardiovascular disease shows that those treated with maximal doses of high-intensity statins had lowest mortality.

Regulatory

- **Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration**
  (15/11/2016) (FirstWord Pharma)
  ABP 215 is the most advanced of the four oncology biosimilar medicines that Amgen and Allergan are collaborating on.

Access

- **Safe healthcare for every woman: the fight continues**
  (16/11/2016) (The Guardian)
  We would never think that in Australia a person could be denied safe access to health care. Yet, remarkably, this remains the reality for many women.

- **Drug makers are improving access to medicine in poor nations**
  (14/11/2016) (STAT)
  Some companies are partnering to develop needed medicines, others are pledging to waive or abandon patent rights or grant licenses so that generic versions of their drugs become available.

R&D

- **Antibody Leads to Sharp Triglyceride, Cholesterol Drop**
  (15/11/2016) (Science Business)
  An experimental synthetic antibody, evinacumab, was shown in a clinical trial to markedly reduce triglycerides and the types of cholesterol that contribute to heart disease.

- **Why Pharma Needs To Invest In Discovery**
  (15/11/2016) (Forbes.com)
  Merck CEO Kenneth Frazier: “I believe the truly bad bet being made by a few in the industry is to engage in the shortsighted pursuit of profits at the expense of pursuing cures.”

- **Skin bacterium releases enzyme that may protect against damage and disease**
  (14/11/2016) (Medical News Today)
  A study from Lund University investigates a skin bacterium called Propionibacterium acnes with antioxidant properties.